electroCore's Quell Device Shows Significant Pain Reduction in Fibromyalgia Study
Event summary
- electroCore's study in JAMA Network Open found Quell device combined with physical therapy significantly reduced movement-evoked pain in fibromyalgia patients compared to physical therapy alone.
- The trial enrolled 384 participants, with 81% reporting Quell as helpful and 55% continuing daily use.
- Benefits were observed within 30 days and sustained for up to six months.
- Quell is the first and only non-drug, FDA-cleared device indicated for fibromyalgia.
The big picture
electroCore's study positions Quell as a potentially game-changing non-pharmacological treatment for fibromyalgia, a condition affecting 2% to 4% of the population. The results could drive broader adoption of bioelectronic medicine in chronic pain management, challenging traditional drug-based therapies. The company's ability to scale this innovation will depend on regulatory support and integration into existing healthcare frameworks.
What we're watching
- Market Expansion
- How electroCore will leverage these results to expand Quell's market share in fibromyalgia treatment.
- Regulatory Approvals
- Whether the positive study results will accelerate FDA approvals for additional indications or modifications of the Quell device.
- Commercialization Strategy
- The pace at which electroCore can integrate Quell into standard outpatient physical therapy protocols.
Related topics